author-photo

John M. Rossi

9

Papers

1050

Citations

Citation Trend

Filter By

Papers (8) Sort By

Journal Conference Others

Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial

2019 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (669)
Durability of Response in Patients with Refractory Large B Cell Lymphoma Treated with Axicabtagene Ciloleucel in the Pivotal Phase 2 Study, ZUMA-1

2018 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (0)
Axicabtagene Ciloleucel in Patients with Refractory Large B Cell Lymphoma: Outcomes by Prior Lines of Therapy in the Pivotal Phase 2 Study, ZUMA-1

2018 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (1)
Analysis of CAR-T and Immune Cells within the Tumor Micro-Environment of Diffuse Large B-Cell Lymphoma Post CAR-T Treatment By Multiplex Immunofluorescence

2018 Blood
Show All
- Source
- Cite
- Save
Citations (5)
End of Phase 1 Results from Zuma-6: Axicabtagene Ciloleucel (Axi-Cel) in Combination with Atezolizumab for the Treatment of Patients with Refractory Diffuse Large B Cell Lymphoma

2018 Blood
Show All
- Source
- Cite
- Save
Citations (26)
Clinical Response in ZUMA-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory Large B Cell Lymphoma, May Be Influenced by Characteristics of the Pretreatment Tumor Microenvironment (TME)

2018 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (1)
Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma

2017 Molecular Therapy
Show All
- Source
- Cite
- Save
Citations (334)
Adaptive Reuse: Reusing Buildings for Future Generations while Maintaining Connections to the Past.

2003
- John M. Rossi
Show All
- Source
- Cite
- Save
Citations (1)